✦ LIBER ✦

Azacitidine has limited activity in ‘real life’ patients with MDS and AML: a single centre experience

✍ Scribed by Murat Ozbalak; Mustafa Cetiner; Huseyin Bekoz; Elif Birtas Atesoglu; Cem Ar; Ayse Salihoglu; Nukhet Tuzuner; Burhan Ferhanoglu

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P-299 Azacitidine in high-risk MDS patie

✍ Greco, R.; Riva, M.; Ravano, E.; Molteni, A.; Morra, E. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 67 KB

Quality of life in adult patients with h

✍ K. LINDVALL; S. Von MACKENSEN; E. BERNTORP 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 237 KB

P.02.21 SAFETY OF INFLIXIMAB INFUSIONS I

✍ Grossi, L.; Di Tullio, A.M.; Pagliaro, M.; Tavani, R.; Cocciolillo, S.; Ferri, O 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Efficacy and safety of canakinumab thera

✍ Russo, R. A. G.; Melo-Gomes, S.; Lachmann, H. J.; Wynne, K.; Rajput, K.; Elefthe 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 112 KB

Granulocyte transfusions for neutropenic

✍ Y. Ofran; I. Avivi; A. Oliven; I. Oren; T. Zuckerman; L. Bonstein; J. M. Rowe; E 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB

P1155 SAFETY AND EFFICACY OF PEG-IFNa2a

✍ Casu, S.; Balestrieri, C.; Figorilli, F.; Onali, S.; Serra, G.; Chessa, L.; Lai, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 62 KB